Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-1966 and SD-101 in Advanced Malignancies
NCT02731742Phase 1Terminated
- Sponsor
- Merck & Co.
- Start
- Jun 2016
- Primary completion
- Jan 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 1, open-label trial of MK-1966 in malignant neoplasms (advanced stage), sponsored by Merck & Co. Started Jun 2016; status: terminated.
02
Drugs
MK-1966
03
Conditions
malignant neoplasms (advanced stage)
Beyond the preview
Go deeper on NCT02731742.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02731742.